Special Issue "The Role of Toll-Like Receptors (TLRs) in Infection and Inflammation 2.0"

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 14

PMID 39273656

Authors

Ralf Kircheis

Oliver Planz

Affiliations

Soon will be listed here.

Abstract

Toll-like receptors (TLRs) are key players in the innate immune system, in host' first-line defense against pathogens [...].

Citing Articles

Consortium of 2029 and 7247 Strains Shows In Vitro Bactericidal Effect on and, in Combination with Prebiotic, Protects Against Intestinal Barrier Dysfunction.

Abramov V, Kosarev I, Machulin A, Deryusheva E, Priputnevich T, Panin A Antibiotics (Basel). 2025; 13(12.

PMID: 39766533 PMC: 11672454. DOI: 10.3390/antibiotics13121143.

A Novel Subsp. T1 Strain from Cow's Milk: Homeostatic and Antibacterial Activity against ESBL-Producing .

Machulin A, Abramov V, Kosarev I, Deryusheva E, Priputnevich T, Panin A Antibiotics (Basel). 2024; 13(10).

PMID: 39452191 PMC: 11505560. DOI: 10.3390/antibiotics13100924.

References

Dubik M, Marczynska-Grzelak J, Sorensen M, Dieu R, Rusin D, Schioth E . Synergistic Targeting of Innate Receptors TLR7 and NOD2 for Therapeutic Intervention in Multiple Sclerosis. Int J Mol Sci. 2024; 25(13). PMC: 11242768. DOI: 10.3390/ijms25137462. View

Kayesh M, Kohara M, Tsukiyama-Kohara K . An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. Viruses. 2021; 13(11). PMC: 8622245. DOI: 10.3390/v13112302. View

Basith S, Manavalan B, Yoo T, Kim S, Choi S . Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012; 35(8):1297-316. DOI: 10.1007/s12272-012-0802-7. View

Kaushik D, Bhandari R, Kuhad A . TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. Expert Opin Ther Targets. 2021; 25(6):491-508. PMC: 8095161. DOI: 10.1080/14728222.2021.1918103. View

Billod J, Lacetera A, Guzman-Caldentey J, Martin-Santamaria S . Computational Approaches to Toll-Like Receptor 4 Modulation. Molecules. 2016; 21(8). PMC: 6274477. DOI: 10.3390/molecules21080994. View

Zheng M, Karki R, Williams E, Yang D, Fitzpatrick E, Vogel P . TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22(7):829-838. PMC: 8882317. DOI: 10.1038/s41590-021-00937-x. View

Farzan M, Farzan M, Mirzaei Y, Aiman S, Azadegan-Dehkordi F, Bagheri N . Immunoinformatics-based multi-epitope vaccine design for the re-emerging monkeypox virus. Int Immunopharmacol. 2023; 123:110725. DOI: 10.1016/j.intimp.2023.110725. View

Nunnari G, Berretta M, Pinzone M, Di Rosa M, Berretta S, Cunsolo G . Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci. 2012; 16(9):1257-70. View

Sariol A, Perlman S . SARS-CoV-2 takes its Toll. Nat Immunol. 2021; 22(7):801-802. PMC: 8238877. DOI: 10.1038/s41590-021-00962-w. View

10.

Klett J, Reeves J, Oberhauser N, Perez-Regidor L, Martin-Santamaria S . Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling. Curr Top Med Chem. 2014; 14(23):2672-83. DOI: 10.2174/1568026614666141215144831. View

11.

Xiao J, Zhang Y, Wu J, -Chen X, Zou W . HIV/HBV coinfection: understanding the complex interactions and their impact on spontaneous HBV clearance, chronic liver damage, cirrhosis, and hepatocellular carcinoma. AIDS Rev. 2024; 26(1):32-40. DOI: 10.24875/AIDSRev.23000019. View

12.

Mogensen T . Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009; 22(2):240-73, Table of Contents. PMC: 2668232. DOI: 10.1128/CMR.00046-08. View

13.

Martinsen J, Gunst J, Falkesgaard Hojen J, Tolstrup M, Sogaard O . The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Front Immunol. 2020; 11:1112. PMC: 7300204. DOI: 10.3389/fimmu.2020.01112. View

14.

Khanmohammadi S, Rezaei N . Role of Toll-like receptors in the pathogenesis of COVID-19. J Med Virol. 2021; 93(5):2735-2739. PMC: 8014260. DOI: 10.1002/jmv.26826. View

15.

Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol. 2002; 1(2):135-45. DOI: 10.1038/35100529. View

16.

Hernandez J, Schaffer J, Herden C, Pflieger F, Reiche S, Korber S . n-3 Polyunsaturated Fatty Acids Modulate LPS-Induced ARDS and the Lung-Brain Axis of Communication in Wild-Type versus Fat-1 Mice Genetically Modified for Leukotriene B4 Receptor 1 or Chemerin Receptor 23 Knockout. Int J Mol Sci. 2023; 24(17). PMC: 10487657. DOI: 10.3390/ijms241713524. View

17.

Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View

18.

Mueller C . Danger-associated molecular patterns and inflammatory bowel disease: is there a connection?. Dig Dis. 2013; 30 Suppl 3:40-6. DOI: 10.1159/000342600. View

19.

Kayesh M, Kohara M, Tsukiyama-Kohara K . Toll-like Receptor Response to Human Immunodeficiency Virus Type 1 or Co-Infection with Hepatitis B or C Virus: An Overview. Int J Mol Sci. 2023; 24(11). PMC: 10253624. DOI: 10.3390/ijms24119624. View

20.

Naqvi I, Giroux N, Olson L, Morrison S, Llanga T, Akinade T . DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials. 2022; 283:121393. PMC: 8797062. DOI: 10.1016/j.biomaterials.2022.121393. View